AZD2461: Novel PARP Inhibitor for Advanced Breast Cancer Research

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 5 nM, exhibiting strong efficacy in human breast cancer cell lines MCF-7 and SKBR-3 (APExBIO). It induces cell cycle arrest at the G2 phase and reduces S phase populations in vitro. In vivo, AZD2461 prolongs median relapse-free survival and is well-tolerated in tumor-bearing mice. Its lower affinity for P-glycoprotein (Pgp) helps address drug resistance compared to similar agents such as olaparib (Schwartz, 2022). AZD2461 is insoluble in water but readily dissolves in DMSO and ethanol, facilitating flexible experimental design for cellular and animal models.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes are essential for the detection and repair of single-strand DNA breaks. PARP-1, in particular, catalyzes the transfer of ADP-ribose units from NAD+ to target proteins, modulating DNA repair and programmed cell death mechanisms. Inhibiting PARP-1 disrupts these repair pathways, leading to the accumulation of DNA damage, cell cycle arrest, and apoptosis—events particularly lethal to cells with defective homologous recombination, such as BRCA1-mutated breast cancer cells (Schwartz, 2022). Overexpression of P-glycoprotein (Pgp), a membrane-bound efflux transporter, limits the efficacy of many chemotherapeutic agents by reducing intracellular drug concentrations. AZD2461 was developed to maintain potent PARP-1 inhibition while minimizing Pgp-mediated efflux, thereby improving therapeutic potential in resistant cancer phenotypes.

Mechanism of Action of AZD2461

AZD2461 acts as a competitive inhibitor of PARP-1, binding to the catalytic domain and blocking its enzymatic activity at nanomolar concentrations (IC50 = 5 nM, in vitro). This inhibition prevents PARP-1 from repairing single-strand DNA breaks, resulting in the accumulation of DNA lesions. In breast cancer models, exposure to AZD2461 leads to a marked increase in the proportion of cells arrested in the G2 phase of the cell cycle and a reduction in S phase populations, indicating cell cycle disruption (Schwartz, 2022). PARP activity is suppressed for several hours following administration in vivo, with restoration of PAR levels by 24 hours, highlighting a reversible and controllable pharmacodynamic profile.

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 activity in MCF-7 and SKBR-3 breast cancer cell lines, reducing viable cell numbers in a concentration- and time-dependent manner (Schwartz, 2022, https://doi.org/10.13028/wced-4a32).
• In vivo, AZD2461 administration in KB1P tumor-bearing mice results in sustained PARP inhibition for hours post-dose, with PAR levels returning to baseline within 24 hours (Schwartz, 2022, https://doi.org/10.13028/wced-4a32).
• Long-term dosing of AZD2461 is well tolerated and significantly prolongs median relapse-free survival in preclinical BRCA1-mutated tumor models (Schwartz, 2022, https://doi.org/10.13028/wced-4a32).
• AZD2461 displays lower affinity for P-glycoprotein compared to olaparib, reducing the likelihood of Pgp-mediated drug resistance (APExBIO, https://www.apexbt.com/azd2461.html).
• Optimal in vitro experimental concentrations are 5–50 μM, with incubation times of 48–72 hours for robust viability and cytotoxicity assays (APExBIO, https://www.apexbt.com/azd2461.html).

For a broader context on how AZD2461 contrasts with other PARP inhibitors, see "AZD2461 in Breast Cancer: Redefining PARP Inhibition and ...". This article expands on the differentiation by integrating recent in vivo survival outcomes and resistance mechanism insights not covered in earlier analyses.

Applications, Limits & Misconceptions

AZD2461 is optimized for research into DNA repair pathway modulation, particularly in breast cancer models with BRCA1 or related homologous recombination deficiencies. Its properties make it valuable for studies targeting relapse-free survival, overcoming drug resistance, and evaluating cell cycle perturbation. APExBIO (SKU A4164) provides detailed solubility and storage guidelines to ensure reproducibility (AZD2461 product page).

• Use in advanced cell-based and in vivo models, especially for Pgp-mediated drug resistance studies ("AZD2461: Novel PARP Inhibitor Workflows in Breast Cancer ..."). This article provides workflow details; the current page updates with new in vivo benchmarks and longer-term survival data.
• AZD2461 is not a panacea: efficacy depends on the genetic background of the cancer model, and its impact is greatest in HR-deficient cells.

Common Pitfalls or Misconceptions

• Not effective in Pgp-overexpressing models if other resistance mechanisms exist: While AZD2461 reduces Pgp-mediated efflux, cells with multi-drug resistance via other pathways may still evade cytotoxicity (Schwartz, 2022).
• Water insolubility limits direct aqueous applications: AZD2461 requires dissolution in DMSO or ethanol, and improper solubilization can cause inconsistent dosing (APExBIO).
• Short solution stability: Solutions should be freshly prepared; long-term storage in solution leads to degradation (APExBIO).
• Not interchangeable with all PARP inhibitors: Lower Pgp affinity does not equate to universal efficacy; mechanism-based differences between inhibitors persist (see comparative article).
• Relapse-free survival extension observed only in specific in vivo models: Translational impact in humans remains to be established; current claims are limited to preclinical settings (Schwartz, 2022).

Workflow Integration & Parameters

For reproducible results, AZD2461 should be handled as follows:

• Solubility: Insoluble in water; soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonication).
• Storage: Store the solid at -20°C. Use prepared solutions immediately; avoid prolonged storage.
• Concentration: Recommended for cell culture at 5–50 μM, with 48–72-hour incubation.
• Models: Suitable for use in MCF-7, SKBR-3, and KB1P tumor models (Schwartz, 2022).
• Product support: The A4164 kit from APExBIO provides validated protocols and reference data for standard and advanced workflows.

For protocol refinements and troubleshooting, see "AZD2461: Novel PARP Inhibitor for Breast Cancer Research". This resource offers application-driven guidance; the present article adds new benchmarks and clarifies storage/solubility issues.

Conclusion & Outlook

AZD2461 exemplifies the next generation of PARP inhibitors for preclinical breast cancer studies, with robust activity, tolerable profiles, and mechanisms addressing key resistance pathways. While its clinical translation remains under investigation, AZD2461 provides researchers with a reliable platform for dissecting DNA repair dynamics, cell cycle arrest, and relapse-free survival in HR-deficient tumor models. For current best practices and up-to-date product data, refer to the official APExBIO AZD2461 product page. Future integration with emerging in vitro assessment methods is expected to further define its translational value (Schwartz, 2022).